Bio-Rad grants Nanogen licence to HH (hereditary haemochromatosis) gene mutations:
This article was originally published in Clinica
Hercules, California-based Bio-Rad has granted Nanogen a licence to the C282Y and H63D gene mutations of the hereditary haemochromatosis (HH) disorder, which results in excessive iron build-up in tissues and major organs of the body. The licence is for use on Nanogen's proprietary NanoChip system for the detection of genetic mutations. Earlier this month, Nanogen, of San Diego, California, was granted a US patent covering methods for detecting certain mutations linked to the condition (see Clinica No 1011, p 2).
You may also be interested in...
Pharma manufacturing is operating well below normal levels in India, disrupted by labor absenteeism and supply chain issues amid the ongoing lock-down in the country, though the government is actively engaged in addressing bottlenecks. A speedy recovery is vital not just for domestic supplies.
Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.
Latest warnings also include second and third businesses in US cannabidiol and hemp sector found making unlawful claims for treating and preventing COVID-19. Four of five firms warned apparently responded by removing violative claims from websites and social media posts.